雾化吸入布地奈德与可必特对慢性阻塞性肺疾病急性加重期患者的疗效

目的 探讨布地奈德与可必特联合雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)的疗效.方法 选择AECOPD患者54例,分为3组.每组18例.布地奈德组(A组)给予布地奈德混悬液2ml,喷射雾化吸入,每12h一次;联合组(B组)给予布地奈德混悬液2ml,可必特2.5ml喷射雾化吸入,每12h一次;对照组(C组)不使用任何吸入荆.观察期为7d.结果 治疗后3组患者动脉血氧分压(PaO2)、动脉二氧化碳分压(PBCO2)、pH值、第一秒钟用力呼气容积、用力肺活量、深吸气量间差异均有统计学意义(P＜0.05);治疗后A组、B组各项观察指标与C组比较,差异均有统计学意义(P＜0.05).结论 联合雾化吸入布地奈德与可必特能更好地改善AE-COPD患者的气流受限.疗效优于单纯吸入布地奈德.

Effects of Budesonide Suspension Combined with Combivent Inhaled on Patients with Acute Exacerbation of COPD

Objective To discussion the efficacy of nebulized budesonide suspension and budesonide suspension combined with Combivent in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods Fifty-four patients with AECOPD were divided into three groups,with 18 in each group.The patients in group A received budesonide nebulized suspension,2mg every 12h;those in group B underwent budesonide suspension 2ml plus combined Combivent 2.5ml by nebulization every 12h;those in group C as the control were not given any bronchodilator drugs and corticosteroids.Observation period was seven days.Results After treatment among the three groups there ware significant differences in arterial oxygenation (PaO2),arterial partial pressure of carbon dioxide (PaCO2),pH value,first-second forced expiratory volume (FEV1),forced vital capacity (FVC) and inspiratory capacity (IC) (P<0.05);compared with the control group,the above parameters in both group A and B were significantly different (P<0.05).Conclusion Nebulized budesonide suspension combined with Combivent can improve airflow in AECOPD patients,which is better than budesonide nebulized suspension alone.